Kureha cut FY ending March 2026 earnings guidance, citing ¥36.5 bn total plant writedowns.
¥34 bn writedown on PVDF plant for lithium‑ion battery material and ¥2.5 bn on Kremezin drug plant were disclosed.
The company also announced a dividend reduction and forfeiture of officer remuneration while noting gains from asset sales and cost cuts.
The writedowns reflect weakening demand in European and US EV markets for specialty ternary lithium‑ion batteries.